Montes Claros

Researchers are evaluating the ability of the drug LXE408 to clear or reduce parasites in the blood of people with chronic Chagas disease who do not have severe organ dysfunction. This phase 2, proof-of-concept, randomized, participant- and investigator-blinded study compares LXE408 to placebo and the standard treatment benznidazole. The study aims to assess the effectiveness, safety, how the drug moves through and affects the body, and tolerability of LXE408 in adults with chronic indeterminate Chagas disease. The study includes four treatment groups with LXE408, placebo, and benznidazole administered orally. Participants receive the assigned treatments according to the study protocol. The study design is parallel group controlled, ensuring participants receive only their assigned treatment. Specific dosing details and treatment duration are outlined in the study plan. Participants will be monitored through visits that include blood tests using polymerase chain reaction (PCR) to check for parasite clearance at 2, 4, and 6 months after treatment starts. Safety and efficacy will be evaluated through clinical assessments, laboratory tests, and participant questionnaires. The study tracks how well participants adhere to the treatment and monitors for any side effects, with follow-up lasting at least six months to observe sustained parasite clearance.

Researchers are conducting an observational study to create a registry of Brazilian patients with hereditary cardiovascular diseases by combining clinical data with genomic information. The study aims to identify which genes are most commonly affected and determine the frequency of these genetic changes in the population. Participants have hereditary cardiovascular conditions such as various types of cardiomyopathy, familial hypercholesterolemia, Marfan syndrome, and other related syndromes. Participants undergo whole genome sequencing using DNA collected from a buccal swab to analyze their genetic makeup. This sequencing serves as a diagnostic test to explore genetic diversity and variant frequency related to their conditions. The genetic information is collected as part of routine medical care visits at multiple centers within Brazil's Unified Health System. During the study, participants will be interviewed and provide clinical information for the registry. Researchers will measure outcomes including diagnostic yield, genetic diversity, and variant frequency 30 months after the study start. Participants must consent to genetic counseling and provide informed consent. The study focuses on collecting detailed clinical and genomic data to better understand hereditary cardiovascular diseases in Brazil.

Researchers are evaluating several repurposed therapies including Fluvoxamine plus Budesonide, Fluoxetine plus Budesonide, and Spirulin Platensis to treat patients with early-onset COVID-19 who have mild symptoms but are at high risk for complications. This phase 3, double-blind, randomized, placebo-controlled study aims to assess if these treatments can reduce emergency care visits, hospitalizations, and oxygen desaturation events related to COVID-19 progression. The study builds on observational and experimental evidence suggesting these agents may have anti-inflammatory effects beneficial in early SARS-CoV-2 infection. Participants receive one of the study treatments or placebo following specific dosing schedules: Spirulin Platensis is given as two tablets every 12 hours for 10 days; Fluvoxamine plus Budesonide involves Fluvoxamine tablets every 12 hours and Budesonide inhalation every 12 hours for 10 days; Fluoxetine plus Budesonide is administered as Fluoxetine tablets daily plus Budesonide inhalation every 12 hours for 7 days. Placebo groups receive matching oral and inhalation placebos or paracetamol as an active comparator. The study includes adaptive modifications such as the addition of new treatment arms and changes to primary endpoints. During the 28-day follow-up, participants are monitored for emergency visits due to worsening COVID-19, hospitalizations related to disease progression, and oxygen saturation levels. Researchers evaluate safety and treatment effects through clinical assessments, laboratory tests, and symptom tracking. Participants must consent to treatment and follow study procedures, with ongoing monitoring for adverse events and protocol adherence throughout the study period.